Targeted Therapy in Breast Cancer
The HER-2/neu Gene and Protein
Jeffrey S. Ross
,
,¶,
Jonathan A. Fletcher||,
Kenneth J. Bloom**,
Gerald P. Linette
,
,
James Stec
,
W. Fraser Symmans
,
Lajos Pusztai
and
Gabriel N. Hortobagyi
From the
Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208;
Division of Molecular Medicine, Millennium Pharmaceuticals, Inc., Cambridge, MA 01238; || Department of Pathology, Brigham Womens Hospital and Harvard Medical School, 75 Francis Street, Boston, MA 02115; ** US Labs, Inc., 2601 Campus Drive, Irvine, CA 92612; 
Department of Medicine, Washington University, St. Louis, MO 63110; 
Departments of Medicine and Pathology, MD Anderson Cancer Center, Houston, TX 77030
 |
ABSTRACT
|
---|
The HER-2/neu oncogene, a member of the epidermal growth factor receptor or erb gene family, encodes a transmembrane tyrosine kinase receptor that has been linked to prognosis and response to therapy with the anti-HER-2-humanized monoclonal antibody, trastuzumab (Herceptin, Genentech, South San Francisco, CA) in patients with advanced metastatic breast cancer. HER-2/neu status has also been tested for its ability to predict the response of breast cancer to other therapies including hormonal therapies, topoisomerase inhibitors, and anthracyclines. This review includes an analysis of 80 published studies encompassing more than 25,000 patients designed to consider the relative advantages and disadvantages of the various methods of measuring HER-2/neu in clinical breast cancer specimens. Southern blotting, PCR amplification detection, and fluorescence in situ hybridization assays designed to detect HER-2/neu gene amplification are compared with HER-2/neu protein overexpression assays performed by immunohistochemical techniques applied to frozen and paraffin-embedded tissues and enzyme immunoassays performed on tumor cytosols. The significance of HER-2/neu overexpression in ductal carcinoma in situ and the HER-2/neu status in uncommon female breast conditions and male breast cancer are also considered. The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is reviewed along with the current studies designed to test whether HER-2/neu status can predict the response to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation. The review will also evaluate the status of serum-based testing for circulating HER-2/neu receptor protein and its ability to predict disease outcome and therapy response.
The HER-2/neu (C-erbB-2) gene is localized to chromosome 17q and encodes a transmembrane tyrosine kinase receptor protein (Fig. 1) that is a member of the epidermal growth factor receptor (EGFR)1 or HER family (Fig. 2) (1). This family of receptors is involved in cell-cell and cell-stromal communication primarily through a process known as signal transduction, in which external growth factors, or ligands, affect the transcription of various genes by phosphorylating or dephosphorylating a series of transmembrane proteins and intracellular signaling intermediates, many of which possess enzymatic activity. Signal propagation occurs as the enzymatic activity of one protein turns on the enzymatic activity of the next protein in the pathway (2). Major pathways involved in signal transduction, including the Ras/mitogen-activated protein kinase (MAPK) pathway, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, the Janus kinase(JAK)/signal transducers and activators of transcription (STAT) pathway, and the phospholipase C
(PLC-
) pathway, ultimately affect cell proliferation, survival, motility, and adhesion (Fig. 3).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1. The HER-2/neu tyrosine kinase receptor. The extracellular domain is recognized by the antibody 4D5, which is the murine antigen binding component of the humanized anti-HER-2/neu antibody trastuzumab (HerceptinTM).
|
|

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 2. The HER (erb) gene family. Note that HER-2/neu has no known ligands and that HER-3 has no intrinsic tyrosine kinase activity.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 3. Dimerization and downstream signaling of the HER (EGFR) family. Major pathways involved in signal transduction, including the Ras, MAPK, PI3K/Akt, JAK/STAT, and the PLC- pathway ultimately affect cell proliferation, cell survival, motility and adhesion.
|
|
Receptor activation requires three variables, a ligand, a receptor, and a dimerization partner (Fig. 2) (3). After a ligand binds to a receptor, that receptor must interact with another receptor of identical or related structure in a process known as dimerization, in order to trigger phosphorylation and activate signaling cascades. Therefore, after ligand binding to an EGFR family member, the receptor can dimerize with various members of the family (EGFR, HER-2, HER3, or HER-4). It may dimerize with a like member of the family (homodimerization), or it may dimerize with a different member of the family (heterodimerization) (Table I). The specific tyrosine residues on the intracellular portion of the HER-2/neu receptor protein that are phosphorylated, and hence the signaling pathways that are activated, depends on the ligand and dimerization partner. The wide variety of ligands and intracellular cross talk with other pathways allow for significant diversity in signaling. While no known ligand for the HER-2/neu receptor has been identified, it is the preferred dimerization partner of the other family members. HER-2/neu heterodimers are more stable (4) and their signaling is more potent (5) than receptor combinations without HER-2/neu. HER-2/neu gene amplification and/or protein overexpression has been identified in 1034% of invasive breast cancers (1).
 |
BACKGROUND AND CLINICAL RELEVANCE
|
---|
Serum HER-2/neu Antigen Levels as a Tumor Marker
Circulating HER-2/neu receptor protein levels have successfully predicted the presence and progression of HER-2/neu-positive breast cancer. In 20 published studies on 4,088 patients, 16 (73%) studies involving 3,458 (85%) of the patients reported a significant correlation of serum HER-2/neu protein levels with disease recurrence, metastasis, or shortened survival (625). Two studies involving 379 patients reported no significant association of serum levels with prognosis (22, 23). Of the 11 studies in which serum HER-2/neu protein levels were tested for their ability to predict response to therapy, 8 (73%) of the studies found that elevated serum HER-2/neu protein levels predicted therapy resistance (8, 1618, 21), whereas three additional studies did not demonstrate this association (15, 23, 25). Serum HER-2/neu levels have correlated with decreased survival and absence of clinical response to hormonal therapy in estrogen receptor (ER)-positive tumors in some studies (13, 21), but not in others (23). Serum HER-2/neu protein measurements have successfully predicted resistance to high-dose chemotherapy (1618), bone marrow transplantation (17), and response to trastuzumab single agent and combination treatment for metastatic HER-2/neu-positive disease (2629).
HER-2/neu Expression and Breast Pathology
HER-2/neu overexpression has been consistently associated with higher grade and extensive forms of ductal carcinoma in situ (3032). HER-2/neu gene amplification occurs at a lower rate (less than 10%) and has been linked to an adverse outcome in invasive lobular carcinoma (33). The frequency of HER-2/neu gene amplification appears to be strongly correlated with tumor grade and ductal versus lobular status. Only 1 of 73 grade I invasive ductal carcinomas and 1 of 67 classic lobular carcinomas showed amplification of the HER-2 gene. HER-2/neu overexpression has been a consistent feature of both mammary and extramammary Pagets disease (3436). The majority of studies that have compared the HER-2/neu status in paired primary and metastatic tumor tissues have found an overwhelming consistency of the patients status regardless of the method of testing (immunohistochemistry (IHC) versus fluorescence in situ hybridization (FISH)) (3742). In one study of node-positive tumors that were defined as biclonal by DNA ploidy profile, HER-2/neu status was determined by IHC in 17 primary tumors and their 82 axillary lymph node metastases (42). Despite this apparent heterogeneity of the predominant clone measured by ploidy status, in each metastatic site the HER-2/neu status was consistent between primary tumors and their corresponding metastases (42). HER-2/neu amplification and overexpression has been associated with adverse outcome in some studies of male breast carcinoma (4346), but not in others (4749). Finally, low-level HER-2/neu overexpression has been identified in benign breast disease biopsies and associated with an increased risk of subsequent invasive breast cancer (50).
Interaction of HER-2/neu Expression with Other Prognosis Variables
HER-2/neu gene amplification and protein overexpression have been associated consistently with high tumor grade, DNA aneuploidy, high cell proliferation rate, negative assays for nuclear protein receptors for estrogen and progesterone, p53 mutation, topoisomerase IIa amplification, and alterations in a variety of other molecular biomarkers of breast cancer invasiveness and metastasis (1, 5056).
Phosphorylated HER2 as a Potential Prognostic and Predictive Marker
It has been argued that one potential confounding aspect of the existing HER-2 tests is that they only detect gene amplification or protein overexpression that does not necessarily reflect the functional activity of the receptor. If HER-2 is truly important in the pathobiology of breast cancer, the receptor must be activated to exert its effects. A common feature of signal transduction through membrane-bound receptor tyrosine kinases is autophosphorylation of the receptor. Autophosphorylation of HER-2, therefore, may be used as a surrogate for active signaling. Monoclonal antibodies have been developed to detect autophosphorylated HER-2 by IHC (57). In invasive breast cancer with HER-2 overexpression, the receptor appears to be activated only in a small subset (12%) of patients (57, 58). Interestingly, the proportion of cases with phosphorylated HER-2 appears to be greater (58%) in ductal carcinoma in situ (59). In one large study of 800 cases of invasive breast cancer with HER-2 overexpression, only cases with phosphorylated HER-2 displayed adverse prognosis (58). Cases with overexpressed but unphosphorylated receptor had a prognosis as favorable as non-HER-2-overexpressing cases, which supports the concept that phopsho-HER-2 may be a more powerful prognostic marker than overall HER-2 protein overexpression. The role of phosphorylated HER-2 as a predictor to trastuzumab therapy is currently unknown. Tissue specimens from the pivotal Herceptin studies are being re-analyzed to answer this very important question.
 |
TESTING FOR HER-2/neu STATUS IN BREAST CANCER
|
---|
Both morphology-based and molecular-based techniques have been used to measure HER-2/neu status in breast cancer clinical samples (Table II) (33, 60138). Of the 80 studies considering 26,309 patients listed in Table III, 72 (90%) of the studies and 24,314 (92%) of the cases found that either HER-2/neu gene amplification or HER-2 (p185 neu) protein overexpression predicted breast cancer outcome on either univariate or multivariate analysis. In 51 (71%) of the 72 studies that featured multivariate analysis of outcome data, the adverse prognostic significance of HER-2/neu gene, message, or protein overexpression was independent of all other prognostic variables. Thirteen (16%) of the studies reported prognostic significance on univariate analysis only (in eight studies multivariate analysis was not performed). Only eight (10%) of the studies, encompassing 1,995 (8%) of the patients, showed no correlation between HER-2/neu status and outcome. Of these eight studies, five (63%) used IHC on paraffin-embedded tissues as the HER-2/protein detection technique, two (25%) used Southern analysis, and one (13%) used a reverse transcription PCR (RT-PCR) technique. All eight studies that used the FISH technique showed univariate prognostic significance of gene amplification, and seven of these (83%) showed prognostic significance on multivariate analysis as well.
 |
HER-2/neu TESTING TECHNIQUES
|
---|
IHC staining (Fig. 4A) has been the predominant method utilized. Unlike most immunohistochemical assays, the assessment of HER-2/neu status is quantitative rather than qualitative, because HER-2/neu is expressed in all breast epithelial cells. In order to provide a meaningful interpretation of a HER-2/neu immunostain, it was necessary to establish a relationship between the number of HER-2/neu receptors on a cells surface and the distribution and intensity of the immunostain. Utilizing cell lines, it was possible to establish a standardized immunohistochemical procedure and scoring system in which cells containing less than 20,000 receptors would show no staining (0), cells containing
100,000 receptors would show partial membrane staining with less than 10% of the cells showing complete membrane staining (1+), cells containing
500,000 receptors would show light to moderate complete membrane staining in more than 10% of the cells (2+), and cells containing
2,300,000 receptors would show strong, complete membrane staining in more than 10% of the cells (3+). Studies have shown that when a standardized IHC assay is performed on specimens that are carefully fixed, processed, and embedded, there is excellent correlation between gene copy status and protein expression levels (1, 51, 52, 139). However, alterations can be significantly impacted by technical issues, especially in archival fixed paraffin-embedded tissues. Advantages of IHC testing (see Table V) include its wide availability, relatively low cost, easy preservation of stained slides, and use of a familiar routine microscope. Disadvantages of IHC include the impact of preanalytic issues including storage, duration and type of fixation, intensity of antigen retrieval, type of antibody (polyclonal versus monoclonal), nature of system control samples, and, most importantly, the difficulties in applying a subjective slide scoring system. In a study of a large panel of antibodies, Press et al. reported a significant variation in detection rates for HER-2/neu protein by IHC using a large tissue block containing multiple breast tumors (140). Problems with standardization in slide scoring have been recently highlighted in reference to the best method for using HER-2/neu status to predict response to the anti-HER-2/neu antibody therapeutic, trastuzumab (141). Slide scoring can be improved by avoiding specimen edges, retraction artifacts, under- or overfixation, cases with significant staining of benign elements, and tumor cells lacking a complete membranous staining pattern (the so-called "chicken wire" appearance). Recent data presented by the National Surgical Adjuvant Breast Program (NSABP) has shown that certified laboratories, defined as those laboratories performing high-volume HER-2/neu testing and demonstrating high concordance between IHC and FISH results, approach 98% interlaboratory concordance when tumors assessed as 3+ were reanalyzed by both IHC and FISH testing at the NSABP laboratory (142). Because most of the submitting laboratories were reference laboratories that cannot control tissue fixation or storage, it has been suggested that preanalytical issues may not be the major cause of interlaboratory variability. Results from the United Kingdom National External Quality Assessment Scheme for Immunohistochemistry (UK NEQAS-ICC) also suggested that the lack of reproducibility of HER-2/neu scoring between laboratories was not the result of tumor heterogeneity or differences in fixation or processing but rather the result of how the scoring system was applied (143). However, in a recent report, prolonged formalin fixation did not impact on the staining for cell cycle markers such as Ki-67 and p27, but did cause significant degradation in hormone receptor proteins and HER-2/neu (144). The use of a quantitative image analysis system can reduce slide-scoring variability among pathologists, especially in 2+ cases (145). When 130 HER-2/neu-immunostained slides were reviewed by 10 pathologists and then were later reviewed with the aid of image analysis, the use of image analysis eliminated most of the interobserver variability, which was significant by routine microscopy (Fig. 5) (146). Two commercially available HER-2/neu IHC kits, the Dako HerceptestTM and the Ventana PathwayTM, are approved for sale for determining eligibility for patients to receive HerceptinTM by the Food and Drug Administration (FDA).

View larger version (125K):
[in this window]
[in a new window]
|
FIG. 4. HER-2/neu testing in breast cancer. A, HER-2/neu protein expression in infiltrating ductal breast cancer measured by immunohistochemistry using the HerceptestTM slide scoring system. Upper left, 0+ (negative) staining for HER-2/neu protein. This level of staining is typically associated with 15,00025,000 surface receptor molecules per cell and HER-2/neu gene copy to chromosome 17 copy ratios measured by FISH of 1.01.2. Upper right, 1+ staining associated with 80,000110,000 receptors and gene ratio of 1.21.4. Lower left, 2+ staining with membranous distribution, but no total cell encirclement associated with 370,000630,000 receptors and gene ratio of 1.42.4. Lower right, 3+ staining with diffuse positive membranous distribution, total cell encirclement and "chicken wire" appearance associated with 2,000,00010,000,000 receptors and gene ratio of 3.45.6 (peroxidase-anti-peroxidase with HerceptestTM antibody x200). (Receptor count and FISH gene ratio data provided by Dr. Kenneth Bloom, US Labs, Inc., Irvine, CA.) B, HER-2/neu gene amplification in infiltrating ductal breast cancer detected by FISH. Left, HER-2/neu gene amplification demonstrated by the Abbott-Vysis PathvysionTM method showing significant increase in HER-2/neu gene signals (red) compared with chromosome 17 signals (green) with a HER-2/neu gene ratio of 3.9. Right, HER-2/neu gene amplification using the Ventana InformTM method showing another breast cancer specimen with an absolute (raw) HER-2/neu gene copy number of 24. C, HER-2/neu gene amplification in infiltrating breast cancer detected by CISH using anti-HER-2/neu probe and IHC with diaminobenzidine chromagen (SpotLightTM HER-2/neu probe, Zymed Laboratories Inc., South San Francisco, CA).
|
|

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 5. Image analysis and HER-2/neu slide scoring. Interobserver variability among 10 pathologists reviewing the same 130 HER-2/neu immunostained slides. Concordance with gene amplification status, assessed by FISH, is plotted on the y-axis. Slides assessed as 2+ or 3+ were called positive. Manual assessment showed significant interobserver variability, while assessment with the aid of image analysis showed little variability. Additionally all pathologists improved their concordance with the aid of image analysis.
|
|
Southern and slot blotting were the first gene-based HER-2/neu detection methods used in breast cancer specimens. These methods can be significantly hampered when tumor cell DNA extracted from the primary carcinoma sample is diluted by DNA from benign breast tissue and inflammatory cells. The FISH technique (Fig. 4B), which is morphology-driven and like IHC can be automated, has the advantages of a more objective scoring system and the presence of a built-in internal control consisting of the two HER-2/neu gene signals present in all non-neoplastic cells in the specimen. Disadvantages of FISH testing include the higher cost of each test, longer time required for slide scoring, requirement of a fluorescent microscope, the inability to preserve the slides for storage and review, and occasionally in identifying the invasive tumor cells. Two versions of the FISH assay are FDA-approved; the Ventana InformTM test that measures only HER-2/neu gene copies and the Abbott-Vysis PathvysionTM test that includes a chromosome 17 probe in a dual color format. Published studies indicate that the two assays are highly correlative (147). The advantages and disadvantages of IHC- and FISH-based HER-2/neu testing are summarized in Table IV.
The chromogenic in situ hybridization method or CISH technique (Fig. 4C) features the advantages of both IHC (routine microscope, lower cost, familiarity) and FISH (built-in internal control, subjective scoring, the more robust DNA target), but is not, to date, FDA-approved for selecting patient eligibility for trastuzumab treatment (148, 149). In a recent study using both FISH and CISH to assay 31 cases of infiltrating breast carcinoma with testing performed in laboratories at two institutions, identical results for both methods were found in 26 (84%) of the cases (150). The CISH and IHC detection methods can be combined, so as to provide simultaneous evaluation of gene copy number and protein expression (Fig. 6), but such methods are experimental and have not yet been adopted in clinical practice.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 6. Simultaneous HER-2/neu gene amplification and protein overexpression determination. HER-2/neu combined gene and protein evaluation in pleural effusion by CISH (DAB, brown) and immunohistochemistry (vector, blue), respectively. A single breast carcinoma cell with HER-2/neu gene amplification and protein overexpression is seen among nonneoplastic cells.
|
|
The RT-PCR technique (151, 152) has predominantly been used to detect HER-2/neu mRNA in peripheral blood and bone marrow samples, has correlated more with gene amplification status than IHC levels (153), and has failed to predict survival but did correlate with ER/progesterone receptor (PR) and tumor grade status in one breast cancer outcome study of 365 patients (121). With the advent of laser capture microscopy and the acceptance of RT-PCR as a routine and reproducible laboratory technique, the use RT-PCR to assess HER-2/neu status may increase in the future.
The cDNA microarray-based method (Fig. 7) of detecting HER-2/neu mRNA expression levels has recently achieved interest as an alternative method for measuring HER-2/neu status in breast cancer (154156). This method has the advantage of being able to assess downstream signaling of the HER-2 pathway at the same time the level of HER-2 mRNA is measured. Other pathways relevant to HER-2 such as the ER pathway can also be assessed simultaneously with this technique. In a recent study, the HER-2/neu gene amplification status detected by FISH on 20 paraffin-embedded breast cancer core biopsy samples was correctly predicted in all cases by the quantification of the HER-2 mRNA levels obtained by expression profiling of mRNA extracted from paired fine needle aspiration biopsies from the same patients (154). Tissue microarrays have also been recently introduced into breast cancer research and have shown excellent correlation with FISH and IHC HER-2/neu results obtained from the donor tissue blocks used to produce the array (157163).

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 7. HER-2/neu mRNA detection by gene expression profiling. A, cluster analysis of transcriptional profile of a series of primary stages I-III invasive breast cancers that were sampled by fine needle aspiration (FNA) biopsy prior to the commencement of neoadjuvant chemotherapy. After mRNA extraction, mRNA expression profiling was performed using the Affymetrix u133 GeneChipTM oligonucleotide microarray system (Affymetrix, Santa Clara, CA). Heat map demonstrates a series of six genes at chromosomal locus 17q12 that were co-amplified with HER-2/neu in a significant number of cases. B, comparison of HER-2/neu mRNA expression levels measured by transcriptional profiling on 32 FNA samples and HER-2/neu gene amplification status determined by FISH on the corresponding core biopsy specimen. Note the close correlation of gene expression with amplification status. (Original data from Pusztai et al., Ref. 114). C, hierarchical clustering after transcriptional profiling of 26 infiltrating breast cancer specimens sampled by FNA using a 62-gene model (25 genes for determining ER status and 37 genes for determining HER-2/neu status). Note the clustering of the HER-2/neu-positive cases and their separation from the HER-2/neu-negative cases. The HER-2/neu-negative ER-positive and HER-2/neu-negative ER-negative tumors can also be separated by this technique. (Original data from Pusztai et al., Ref. 114.)
|
|
The enzyme-linked immunosorbent assay (ELISA) technique when performed on tumor cytosols made from fresh tissue samples avoids the potential antigen damage associated with fixation, embedding, and uncontrolled storage. In the six published studies listed in Table III, ELISA-based measurements of HER-2/neu protein in tumor cytosols, mostly performed in Europe, have uniformly correlated with disease outcome (102, 104, 123, 125, 127, 138). In a recent study from Europe, the results of ELISA measurements on tumor extracts correlated closely with both HER-2/neu gene amplification results detected by FISH and protein expression results measured by IHC (164). However, the small size of breast cancers associated with expanded screening programs in the United States generally precludes tumor tissue ELISA methods because insufficient tumor tissue is available to produce a cytosol.
 |
TRASTUZUMAB (HERCEPTINTM)
|
---|
Using recombinant technologies, trastuzumab, a monoclonal IgG1 class-humanized murine antibody (Fig. 8), was developed by Genentech (South San Francisco, CA) to specifically bind the extracellular portion of HER-2/neu. This antibody therapy was initially targeted specifically for patients with advanced relapsed breast cancer that overexpressed the HER-2/neu protein (165). Since its launch in 1998, trastuzumab has become an important therapeutic option for patients with HER-2/neu-positive breast cancer. Trastuzumab is widely used for its approved indication as a second line of treatment for advanced metastatic disease, and is also being studied in adjuvant treatment for earlier-stage disease and in neo-adjuvant treatment protocols (166169). Using a clinical trial IHC assay to select patients for the phase III pivot trial, the addition of trastuzumab to chemotherapy (either anthracycline plus cyclophosphamide or taxane) was associated with a longer time to disease progression (median 7.4 versus 4.6 months; p < 0.001), a higher rate of objective response (50% versus 32%; p < 0.001), a longer duration of response (median 9.1 versus 6.1 months; p < 0.001), a lower rate of death at 1 year (22% versus 33%; p = 0.008), longer survival (median survival 25.1 versus 20.3 months; p = 0.01), and a 20% reduction in the risk of death (170). Although not completely understood at this time, mechanisms believed to be associated with the anti-tumor effects of trastuzumab are listed in Table V.

View larger version (60K):
[in this window]
[in a new window]
|
FIG. 8. Trastuzumab (HerceptinTM). The trastuzumab molecule includes the murine 4D5 antigen recognition antibody and the human IgG1 class antibody structure.
|
|
In the original pivot trial, class III or IV cardiac dysfunction occurred in 27% of the anthracycline and cyclophosphamide plus trastuzumab-treated group compared with 8% of the group given an anthracycline and cyclophosphamide alone (170). Cardiac toxicity has remained a significant limiting factor for the use of trastuzumab since its FDA approval in late 1998 (171). Studies have demonstrated that HER-2 and HER-4 with its ligand heregulin are necessary for normal development of the heart, and knockout mice that lack the HER-2/neu gene expression in their cardiac myocytes develop progressive dilated cardiomyopathy (172). This has led to the development of nonanthracycline-containing regimens combining trastuzumab with taxanes and platinins (173). Preliminary data from phase II studies of these combinations have generated promising results (174), and a recent report listed a time to progression of 17 months for patients with HER-2/neu-amplified metastatic breast cancer treated with the combination of docetaxel, carboplatin, and trastuzumab (175).
 |
PREDICTING RESPONSE TO THERAPY
|
---|
HER-2/neu Status and the Prediction of Response to Trastuzumab Therapy
The best method to identify patients who may respond to trastuzumab therapy has been a source of controversy. The original IHC technique used in the trastuzumab pivot trial was the clinical trial assay (CTA), which consisted of two antibodies: 1) 4D5, the monoclonal antibody that is the actual antigen-binding murine component of HerceptinTM and is not commercially available, and 2) CB-11, a monoclonal antibody directed toward the internal domain of the p185neu receptor that is commercially available both as a research reagent and as an FDA-approved diagnostic (PathwayTM, Ventana Medical Systems, Tucson, AZ). The original CTA was succeeded by the FDA-approved polyclonal HercepTest® (Dako, Glostrup, Denmark). There is good concordance between the CTA and HercepTest®, although 58 of 274 tumors that scored as positive with the CTA were scored as negative with HercepTest® and 59 of 274 tumors that scored as negative with the CTA were scored as positive with HercepTest® (176). After its FDA-approval and launch, the HercepTest® assay was initially criticized for yielding false-positive results (177), although better performance was ultimately achieved when the test was performed exactly according to the manufacturers instructions. Concern over IHC accuracy using standard formalin-fixed paraffin-embedded tissue sections (141) has encouraged the use of the FISH assay for its ability to predict trastuzumab response rates. Reports that FISH could out-perform IHC in predicting trastuzumab response (Fig. 9) (178) and well-documented lower response rates of 2+ IHC staining versus 3+ staining tumors (128) has resulted in an approach that either uses IHC as a primary screen with FISH testing of all 2+ cases or primary FISH-based testing (179). In a recently published study where trastuzumab was used as a single agent, the response rates in 111 assessable patients with 3+ IHC staining was 35% and the response rates for 2+ cases was 0%; the response rates in patients with and without HER-2/neu gene amplification detected by FISH were 34 and 7%, respectively (180). In another study of breast cancer treated with trastuzumab plus paclitaxel, in patients with HER2/neu-overexpressing tumors, overall response rates ranged from 67% to 81% compared with 41% to 46% in patients with normal expression of HER2/neu (181). The CB11 and TAB250 antibodies for IHC and FISH featured the strongest significance (181). Interestingly, in a recent published review from New York and Italy, it was noted that although FISH-based testing is more expensive and not as widely available as IHC, the data suggested that FISH was actually the most cost-effective option (182). Other recent studies have favored the FISH approach not only to confirm 2+ IHC cases but to also confirm 3+ and prevent the use of potentially toxic trastuzumab to patients with false-positive IHC results who are unlikely to benefit from this therapy (183). In summary, while the superiority of one method versus the other remains controversial (139, 184186), most laboratories are either screening all cases with IHC and triaging selected cases for FISH testing or using FISH as the only method for HER-2/neu testing. For the laboratories that use IHC as the primary screen, the decision as to when to triage to FISH testing is also controversial. Some laboratories refer only their 2+ IHC cases, some triage 1+ and 2+, and others refer 1+, 2+, and any other cases where the HER-2/neu IHC results are not consistent with other disease parameters such as grade, stage, ploidy, S phase, and hormone receptor status.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 9. FISH versus IHC and survival in trastuzumab single-agent and combination chemotherapy for advanced metastatic breast cancer. Survival curves demonstrate a significant (p < 0.05) increase in median duration of survival for patients treated with either HerceptinTM alone or HerceptinTM plus chemotherapy in patients whose primary tumors were classified by FISH (PathvysionTM test) for HER-2/neu gene amplification status versus patients who were classified by IHC (Genentech CTA with antibodies 4D5 and CB-11). (Data from Genentech Clinical Trial H-0648 cited by Mass R et al. in Ref. 127.)
|
|
Prediction of Response of Breast Cancer to Other Therapies
The best established correlate between HER-2/neu status and non-HerceptinTM therapy response is the reported resistance of HER-2/neu-positive patients to hormonal therapy alone (28, 187189). Tumors that overexpress HER-2/neu are more likely to be ER-negative and PR-negative than tumors that do not show overexpression. In fact, when measured as continuous variables, the expression of HER-2/neu appears to be inversely related to the expression of ER and PR even in hormone receptor-positive tumors (190). In some studies, HER-2/neu-positive tumors were specifically resistant to tamoxifen therapy (13, 111, 123, 126, 130, 191). However, in other studies, HER-2/neu status failed to predict tamoxifen resistance in ER-positive cases (192). In another study, ER-positive HER-2/neu-positive tumors were not only resistant to tamoxifen, single-agent tamoxifen treatment actually had an adverse impact compared with untreated patients (193). However, this finding has not, to date, been confirmed by large intergroup studies in the United States (194). Most recently, ER-negative HER-2/neu-positive tumors have been associated with an improved response to alternative hormonal therapies such as the aromatase inhibitors (195). HER-2/neu protein overexpression has also been linked to resistance of tumors in patients treated with cytoxan, methotrexate, 5-fluorouracil (CMF) adjuvant chemotherapy (90, 193) as well as to taxane-based regimens (196198). However, in another study, HER-2/neu-positive breast cancers were three times more sensitive to taxol (199). HER-2/neu overexpression has also been associated with enhanced response rates to anthracycline-containing chemotherapy regimens in some, but not all, studies (91, 169, 200204). In a recent study of the response of locally advanced breast cancer to a neoadjuvant chemotherapy regimen consisting of 5-fluoruracil, doxorubicin, and cyclophosphamide, the pretreatment HER-2/neu status detected by IHC was not predictive of treatment response (205).
Because anthracyclines are topoisomerase inhibitors and topoisomerase II
(TOP2A) is frequently co-amplified with HER-2/neu, it has been suggested that HER-2/neu may be serving as a surrogate marker. Cell lines transfected with HER-2/neu and then exposed to doxorubicin in vitro did not show enhanced sensitivity to the chemotherapy relative to the parent cell lines (206). Recently, it was shown that HER-2/neu protein expression, but not TOP2A expression, predicted the response of breast cancer to the anti-topoisomerase anthracycline, epirubicin (207). This is in contrast to another study that claimed that TOP2A gene amplification and deletion seem to account for both relative chemosensitivity and resistance to topoII inhibitors and that TOP2A status occurs in breast cancer independent from the HER-2/neu status (208). However, other studies have consistently linked co-expression and co-amplification of the topoisomerase II
and HER-2/neu genes with adverse prognosis and sensitivity to anthracycline drugs (209214). Finally, HER-2/neu immunostaining has successfully predicted local recurrence in patients receiving surgery and radiation (215216). In summary, although strong trends have been presented in the published studies, including the resistance to tamoxifen and sensitivity to anthracycline regimens for HER-2/neu-positive tumors, more studies are needed using appropriate control arms to confirm these important associations. Should this be accomplished, it would seem likely that HER-2/neu testing, which achieved standard of care status in the American Society of Clinical Oncology breast cancer clinical practice guidelines in 2001, would be of even greater value in the management of breast cancer patients.
 |
SUMMARY AND FUTURE CLINICAL POTENTIAL
|
---|
The testing of newly diagnosed breast cancer specimens for HER-2/neu status has now achieved "standard of practice" status for the management of breast cancer in the United States. The discussion as to the best method to determine HER-2/neu status in these samples continues with the FISH method gaining popularity due to the recent evidence that it, in comparison to IHC, may more accurately predict clinical responses to trastuzumab-based therapies. With trastuzumab achieving excellent results in the treatment of HER-2/neu-positive advanced disease and under extensive evaluation in major clinical trials for its potential efficacy when used earlier, the potential role(s) for HER-2/neu testing as a predictor(s) of responses to other therapies being resolved by large prospective clinical outcome studies and the more convenient gene-based CISH technique "waiting in the wings," the "story" of HER-2/neu testing in breast cancer will continue to unfold over the next several years.
 |
FOOTNOTES
|
---|
Received, January 20, 2004, and in revised form, February 2, 2004.
Published, MCP Papers in Press, February 3, 2004, DOI 10.1074/mcp.R400001-MCP200
1 The abbreviations used are: EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; RT-PCR, reverse transcription PCR; CISH, chromogenic in situ hybridization; ER, estrogen receptor; PR, progesterone receptor; ELISA, enzyme-linked immunosorbent assay; CTA, clinical trial assay. 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 
¶ To whom correspondence should be addressed: Albany Medical College, Department of Pathology, Mail Code 81, 47 New Scotland Avenue, Albany, NY 12208. Tel.: 518-262-5461; Fax: 518-262-8092; E-mail: rossj{at}mail.amc.edu
 |
REFERENCES
|
---|
- Navolanic, P. M., Steelman, L. S., and McCubrey, J. A.
(2003) EGFR family signaling and its association with breast cancer development and resistance to chemotherapy.
Int. J. Oncol.
22, 237
252[Medline]
- Karunagaran, D., Tzahar, E., Beerli, R. R., Chen, X., Graus-Porta, D., Ratzkin, B. J., Seger, R., Hynes, N. E., and Yarden, Y.
(1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer.
EMBO J.
15, 254
264[Abstract]
- Yarden, Y., and Sliwkowski, M. X.
(2001) Untangling the ErbB signalling network.
Nat. Rev. Mol. Cell. Biol.
2, 127
137[CrossRef][Medline]
- Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y.
(1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.
Mol. Cell. Biol.
16, 5276
5287[Abstract]
- Craven, R. J., Lightfoot, H., and Cance, W. G. A.
(2003) A decade of tyrosine kinases: From gene discovery to therapeutics.
Surg. Oncol.
12, 39
49[CrossRef][Medline]
- Isola, J. J., Holli, K., Oksa, H., Teramoto, Y., and Kallioniemi, O. P.
(1994) Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer.
Cancer
73, 652
658[Medline]
- Andersen, T. I., Paus, E., Nesland, J. M., McKenzie, S. J., and Borresen, A. L.
(1995) Detection of C-erb B2 related proteins in sera from breast cancer patients. Relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour.
Acta Oncol.
34, 499
504[Medline]
- Willsher, P. C., Beaver, J., Pinder, S., Bell, J. A., Ellis, I. O., Blamey, R. W., and Robertson, J. F.
(1996) Prognostic significance of serum CerbB2 protein in breast cancer patients.
Breast Cancer Res. Treat.
40, 251
255[Medline]
- Fehm, T., Maimonis, P., Wetz, S., Teramoto, Y., Katalinic, A., and Jager, W.
(1997) Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients.
Breast Cancer Res. Treat.
43, 87
95[CrossRef][Medline]
- Mansour, O. A., Zekri, A. R., Harvey, J., Teramoto, Y., and el-Ahmady, O.
(1997) Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: Three years follow-up.
Anticancer Res.
17, 3101
3106[Medline]
- Disis, M. L., Pupa, S. M., Gralow, J. R., Dittadi, R., Menard, S., and Cheever, M. A.
(1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.
J Clin Oncol
15, 3363
3367[Abstract]
- Krainer, M., Brodowicz, T., Zeillinger, R., Wiltschke, C., Scholten, C., Seifert, M., Kubista, E., and Zielinski, C. C.
(1997) Tissue expression and serum levels of HER-2/neu in patients with breast cancer.
Oncology
54, 475
481[Medline]
- Burke, H. B., Hoang, A., Iglehart, J. D., and Marks, J. R.
(1998) Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma.
Cancer
82, 874
877[CrossRef][Medline]
- Fehm, T., Maimonis, P., Katalinic, A., and Marks, J. R.
(1998) The prognostic significance of c erbB-2 serum protein in metastatic breast cancer.
Oncology
55, 33
38[CrossRef][Medline]
- Mehta, R. R., McDermott, J. H., Hieken, T. J., Marler, K. C., Patel, M. K., Wild, L. D., and Das Gupta, T. K.
(1998) Plasma c-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy.
J. Clin. Oncol.
16, 2409
2416[Abstract]
- Colomer, R., Montero, S., Lluch, A., Ojeda, B., Barnadas, A., Casado, A., Massuti, B., Cortes-Funes, H., and Lloveras, B.
(2000) Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
Clin. Cancer Res.
6, 2356
2362[Abstract/Free Full Text]
- Bewick, M., Conlon, M., Gerard, S., Lee, H., Parissenti, A. M., Zhang, L., Gluck, S., and Lafrenie, R. M.
(2001) HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.
Bone Marrow Transplant.
27, 847
853[CrossRef][Medline]
- Harris, L. N., Liotcheva, V., Broadwater, G., Ramirez, M. J., Maimonis, P., Anderson, S., Everett, T., Harpole, D., Moore, M. B., Berry, D. A., Rizzeri, D., Vredenburgh, J. J., and Bentley, R. C.
(2001) Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy.
J. Clin. Oncol.
19, 1698
1706[Abstract/Free Full Text]
- Ali, S. M., Leitzel, K., Chinchilli, V. M., Engle, L., Demers, L., Harvey, H. A., Carney, W., Allard, J. W., and Lipton, A.
(2002) Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Clin. Chem.
48, 1314
1320[Abstract/Free Full Text]
- Classen, S., Kopp, R., Possinger, K., Weidenhagen, R., Eiermann, W., and Wilmanns, W.
(2002) Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
Tumour Biol.
23, 70
75[CrossRef][Medline]
- Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Chinchilli, V., Engle, L., Harvey, H. A., Brady, C., Nalin, C. M., Dugan, M., Carney, W., and Allard, J.
(2002) Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
J. Clin. Oncol.
20, 1467
1472[Abstract/Free Full Text]
- Kandl, H., Seymour, L., and Bezwoda, W. R.
(1994) Soluble c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer.
Br. J. Cancer
70, 739
742[Medline]
- Volas, G. H., Leitzel, K., Teramoto, Y., Grossberg, H., Demers, L., and Lipton, A.
(1996) Serial serum C-erbB-2 levels in patients with breast carcinoma.
Cancer
78, 267
272[CrossRef][Medline]
- Carney, W. P., Neumann, R., Lipton, A., Leitzel, K., Ali, S., and Price, C. P.
(2003) Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
Clin. Chem.
49, 1579
1598[Abstract/Free Full Text]
- Revillion, F., Hebbar, M., Boneterre, J., and Peyrat, J. P.
(1996) Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients.
Eur. J. Cancer
32a, 231
234[CrossRef][Medline]
- Ali, S. M., Leitzel, K., Chinchilli, V. M., Engle, L., Demers, L., Harvey, H. A., Carney, W., Allard, J. W., and Lipton, A.
(2002) Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Clin. Chem.
48, 1314
1320[Abstract/Free Full Text]
- Lipton, A., Ali, S. M., Leitzel, K., Demers, L., Harvey, H. A., Chaudri-Ross, H. A., Brady, C., Wyld, P., and Carney, W.
(2003) Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
J. Clin. Oncol.
21, 1967
1972[Abstract/Free Full Text]
- Nunes, R. A., and Harris, L. N.
(2002) The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.
Clin. Breast Cancer.
3, 125
135[Medline]
- Slamon, D., and Pegram, M.
(2001) Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Semin. Oncol.
28, 13
19
- Bose, S., Lesser, M. L., Norton, L., and Rosen, P. P.
(1996) Immunophenotype of intraductal carcinoma.
Arch. Pathol. Lab. Med.
120, 81
85[Medline]
- Moreno, A., Lloveras, B., Figueras, A., Escobedo, A., Ramon, J. M., Sierra, A., and Fabra, A.
(1997) Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers.
Mod. Pathol.
10, 1088
1092[Medline]
- Mack, L., Kerkzelit, N., Doig, G., and OMalley, F. P.
(1997) Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67.
Hum. Pathol.
28, 974
979[Medline]
- Rosenthal, S. I., Depowski, P. L., Sheehan, C. E., and Ross, J. S.
(2002) Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer.
Appl. Immunohistochem. Mol. Morphol.
10, 40
46.3[Medline]
- Wolber, R. A., DuPuis, B. A., and Wick, M. R.
(1991) Expression of cerb B2 oncoprotein in mammary and extramammary Pagets disease.
Am. J. Clin. Pathol.
96, 243
247[Medline]
- Fu, W., Lobocki, C. A., and Silberberg, B. K.
(2001) Molecular markers in Paget disease of the breast.
J. Surg. Oncol.
77, 171
178[CrossRef][Medline]
- Hanna, W., Alowami, S., and Malik, A.
(2003) The role of HER-2/neu oncogene and vimentin filaments in the production of the Pagets phenotype.
Breast J.
9, 485
490[CrossRef][Medline]
- Masood, S., and Bui, M. M.
(2000) Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study.
Ann. Clin. Lab. Sci.
30, 259
265[Abstract]
- Dittadi, R., Zancan, M., Perasole, A., and Gion, M.
(2001) Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay.
Int. J. Biol. Markers
16, 255
261[Medline]
- Simon, R., Nocito, A., Hubscher, T., Bucher, C., Torhorst, J., Schraml, P., Bubendorf, L., Mihatsch, M. M., Moch, H., Wilber, K., Schotzau, A., Kononen, J., and Sauter, G.
(2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer.
J. Natl. Cancer Inst.
93, 1141
1146[Abstract/Free Full Text]
- Vincent-Salomon, A., Jouve, M., Genin, P., Freneaux, P., Sigal-Zafrani, B., Caly, M., Beuzeboc, P., Pouillart, P., and Sastre-Garau, X.
(2002) HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Cancer
94, 2169
2173[CrossRef][Medline]
- Xu, R., Perle, M. A., Inghirami, G., Chan, W., Delgado, Y., and Feiner, H.
(2002) Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Mod. Pathol.
15, 116
124[Medline]
- Symmans, W. F., Liu, J., Knowles, D. M., and Inghirami, G.
(1995) Breast cancer heterogeneity: Evaluation of clonality in primary and metastatic lesions.
Hum. Pathol.
26, 210
216[Medline]
- Gattuso, P., Reddy, V. B., Green, L. K., and Bloom, K. J.
(1995) Prognostic factors for carcinoma of the male breast.
Int. J. Surg. Pathol.
2, 199
206
- Joshi, M. G., Lee, A. K., Loda, M., Camus, M. G., Pedersen, C., Heatley, G. J., and Hughes, K. S.
(1996) Male breast carcinoma: An evaluation of prognostic factors contributing to a poorer outcome.
Cancer
77, 490
498[CrossRef][Medline]
- Pich, A., Margaria, E., and Chiusa, L.
(2000) Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
J. Clin. Oncol.
18, 2948
2956[Abstract/Free Full Text]
- Wang-Rodriguez, J., Cross, K., Gallagher, S., Djahanban, M., Armstrong, J. M., Wiedner, N., and Shapiro, D. H.
(2002) Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Mod. Pathol.
15, 853
861[Medline]
- Rayson, D., Erlichman, C., Suman, V. J., Roche, P. C., Wold, L. E., Ingle, J. N., and Donohue, J. H.
(1998) Molecular markers in male breast carcinoma.
Cancer
83, 1947
1955[CrossRef][Medline]
- Shpitz, B., Bomstein, Y., Sternberg, A., Klein, E., Liverant, S., Groisman, G., and Bernheim, J.
(2000) Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer.
J. Surg. Oncol.
75, 252
257[CrossRef][Medline]
- Bloom, K. J., Govil, H., Gattuso, P., Reddy, V., and Francescatti, D.
(2001) Status of HER-2 in male and female breast carcinoma.
Am. J. Surg.
182, 389
392[CrossRef][Medline]
- Stark, A., Hulka, B. S., Joens, S., Novotny, D., Thor, A. D., Wold, L. E., Schell, M. J., Melton, L. J., 3rd, Liu, E. T., and Conway, K.
(2000) HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer.
J. Clin. Oncol.
18, 267
274[Abstract/Free Full Text]
- Hayes, D. F., and Thor, A. D.
(2002) c-erbB-2 in breast cancer: Development of a clinically useful marker.
Semin. Oncol.
29, 231
245[CrossRef][Medline]
- Masood, S., and Bui, M. M.
(2002) Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Microsc. Res. Tech.
59, 102
108[CrossRef][Medline]
- Eccles, S. A.
(2001) The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.
J. Mammary Gland Biol. Neoplasia
6, 393
406[CrossRef][Medline]
- Piccart, M., Lohrisch, C., Di Leo, A., and Larsimont, D.
(2001) The predictive value of HER2 in breast cancer.
Oncology
61, (Suppl. 2)73
82[CrossRef]
- Yarden, Y.
(2001) Biology of HER2 and its importance in breast cancer.
Oncology
61, (Suppl. 2)1
13
- Zemzoum, I., Kates, R. E., Ross, J. S., Dettmar, P., Dutta, M., Henrichs, C., Yurdseven, S., Hofler, H., Kiechle, M., Schmitt, M., and Harbeck, N.
(2003) Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
J. Clin. Oncol.
21, 1022
1028[Abstract/Free Full Text]
- DiGiovanna, M. P., and Stern, D. F.
(1995) Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
Cancer Res.
55, 1946
1955[Abstract]
- Thor, A. D., Liu, S., Edgerton, S., Moore, D., 2nd, Kasowitz, K. M., Benz, C. C., Stern, D. F., and DiGiovanna, M. P.
(2000) Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer.
J. Clin. Oncol.
18, 3230
3239[Abstract/Free Full Text]
- DiGiovanna, M. P., Chu, P., Davison, T. L., Howe, C. L., Carter, D., Claus, E. B., and Stern, D. F.
(2002) Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: Clinicopathological correlates.
Cancer Res.
62, 6667
6673[Abstract/Free Full Text]
- Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L.
(1987) Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene.
Science
235, 177
182[Medline]
- Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., and Hynes, N. E.
(1988) Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading.
Cancer Res.
48, 1238
1243[Abstract]
- van de Vivjer, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R.
(1988) Neu-protein overexpression in breast cancer.
N. Engl. J. Med.
319, 1239
1245[Abstract]
- Heintz, N. H., Leslie, K. O., Rogers, L. A., and Howard, P. L.
(1990) Amplification of the c-erb B 2 oncogene in prognosis of breast adenocarcinoma.
Arch. Pathol. Lab. Med.
114, 160
163[Medline]
- Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., and Horne, C. H.
(1989) Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer.
Cancer Res.
49, 2087
2090[Abstract]
- Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Watanabe, S., Terada, M., and Yamamoto, H.
(1990) Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases.
Cancer
65, 1794
1800[Medline]
- Borg, A., Tandon, A. K., Sigurdsson, H., Clark, G. M., Ferno, M., Fuqua, S. A., Killander, D., and McGuire, W. L.
(1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer.
Cancer Res.
50, 4332
4337[Abstract]
- Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., and King, C. R.
(1990) Pathologic findings from the nations surgical adjuvant breast and bowel project: Prognostic significance of erb B2 protein overexpression in primary breast cancer.
J. Clin. Oncol.
8, 103
112[Abstract]
- Battifora, H., Gaffey, M., Esteban, J., Mehta, P., Bailey, A., Faucett, C., and Niland, J.
(1991) Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases.
Mod. Pathol.
4, 466
474[Medline]
- Kallioniemi, O. P., Holli, K., Visakorpi, T., Koivula, T., Helin, H. H., and Isola, J. J.
(1991) Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.
Int. J. Cancer
49, 650
655[Medline]
- Gullick, W. J., Love, S. B., Wright, C., Barnes, D. M., Gusterson, B., Harris, A. L., and Altman, D. G.
(1991) c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.
Br. J. Cancer
63, 434
438[Medline]
- Clark, G. M., and McGuire, W. L.
(1991) Follow-up study of HER-2/neu amplification in primary breast cancer.
Cancer Res.
51, 944
948[Abstract]
- Lovekin, C., Ellis, I. O., Locker, A., Robertson, J. F., Bell, J., Nicholson, R., Gullick, W. J., Elston, C. W., and Blamey, R. W.
(1991) C-erb B2 oncoprotein expression in primary and advanced breast cancer.
Br. J. Cancer
63, 439
443[Medline]
- McCann, A. H., DeDervan, T. A., ORegan, M., Codd, M. B., Gullick, W. J., Tobin, B. M., and Carney, D. N.
(1991) Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer.
Cancer Res.
51, 3296
3303[Abstract]
- Dykens, R., Corbett, I. P., Henry, J., Wright, C., Yuan, J., Hennessy, C., Lennard, T. J., Angus, B., and Horne, C. H.
(1991) Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11.
J. Pathol.
163, 105
110[Medline]
- Rilke, F., Colnaghi, M. I., Cascinelli, N., Andreola, S., Baldini, M. T., Bufalino, R., Della Porta, G., Menard, S., Pierotti, M. A., and Testori, A.
(1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors.
Int. J. Cancer
49, 44
49[Medline]
- Winstanley, J., Cooke, T., Murray, G. D., Platt-Higgins, A., George, W. D., Holt, S., Myskov, M., Spedding, A., Barraclough, B. R., and Rudland, P. S.
(1991) The long term prognostic significance of C-erb B2 in primary breast cancer.
Br. J. Cancer
63, 447
450[Medline]
- OReilly, S. M., Barnes, D. M., Camplejohn, R. S., Bartkova, J., Gregory, W. M., and Richards, M. A.
(1991) The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer.
Br. J. Cancer
63, 444
446[Medline]
- Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., Lees, A. W., Jamil, N., Hanson, J., Jenkins, H., Krause, B. E., McBlain, W. A., et al.
(1991) Correlation between C erb B2 amplification and risk of recurrent disease in node-negative breast cancer.
Cancer Res.
51, 556
567[Abstract]
- Toikkanen, S., Helin, H., Isola, J., and Joensuu, H.
(1992) Prognostic significance of Her-2 oncoprotein expression in breast cancer: A 30-year follow up.
J. Clin. Oncol.
10, 1044
1048[Abstract]
- Molina, R., Ciocca, D. R., Candon, A. K., Allred, D. C., Clark, G. M., Chamness, G. C., Gullick, W. J., and McGuire, W. L.
(1992) Expression of HER-2/neu oncoprotein in breast cancer: A comparison of immunohistochemical and western blot techniques.
Anticancer Res.
12, 1965
1991[Medline]
- Noguchi, M., Koyasaki, M., Ohta, N., Kitagawa, H., Earashi, M., Thomas, M., Miyazaki, I., and Mizukami, Y.
(1992) c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer.
Cancer
69, 2953
2960[Medline]
- Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L., et al.
(1992) HER-2/neu node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in-situ carcinoma.
J. Clin. Oncol.
10, 599
605[Abstract]
- Babiak, J., Hugh, J., and Poppeme, S.
(1992) Significance of c-erb B-2 amplification in DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer.
Cancer
70, 770
776[Medline]
- Tiwari, R. K., Borgen, P. I., Wong, G. Y., Cordon-Cardo, C., and Osborne, M. P.
(1992) HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Anticancer Res.
12, 419
426[Medline]
- Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R., et al.
(1992) Prognostic importance of C-erb B2 expression in breast cancer.
J. Clin. Oncol.
10, 1049
1056[Abstract]
- Bianchi, S., Paglierani, M., Zampi, G., Cardona, G., Cataliotti, L., Bonardi, R., and Ciatto, S.
(1993) Prognostic significance of C-erb B2 expression in node negative breast cancer.
Br. J. Cancer
67, 625
629[Medline]
- Press, M. F., Pike, M. C., Chazin, V. R., Hung, G., Udove, J. A., Markowicz, M., Danyluk, J., Godolphin, W., Sliwkowski, M., Akita, R., et al.
(1993) Her-2/neu expression in node-negative breast cancer: Direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Cancer Res.
53, 4960
4970[Abstract]
- Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P.
(1993) Clinical significance of Her-2/neu oncogene amplification in primary breast cancer.
J. Clin. Oncol.
11, 1936
1942[Abstract]
- Descotes, F., Pavy, J.-J., and Adessi, G. L.
(1993) Human breast cancer: Correlation study between Her-2/neu amplification and prognostic factors in an unselected population.
Anticancer Res.
13, 119
124[Medline]
- Giai, M., Roagna, R., Ponzone, R., De Bortoli, M., Dati, C., and Sismondi, P.
(1994) Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer.
Anticancer Res.
14, 1441
1450[Medline]
- Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al.
(1994) Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
N. Engl. J. Med.
330, 1260
1266[Abstract/Free Full Text]
- Tetu, B., and Brisson, J.
(1994) Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy.
Cancer
73, 2359
2365[Medline]
- Hartmann, L. C., Ingle, J. N., Wold, L. E., Farr, G. H., Jr., Grill, J. P., Su, J. Q., Maihle, N. J., Krook, J. E., Witzig, T. E., and Roche, P. C.
(1994) Prognostic value of CerbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol.
Cancer
74, 2956
2963[Medline]
- Jacquemeier, J., Penault-Llorca, P., Viens, P., Houvenaeghel, G., Hassoun, J., Torrente, M., Adelaide, J., and Birnbaum, D.
(1994) Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression.
Anticancer Res.
14, 2773
2778[Medline]
- Marks, J. R., Humphrey, P. A., Wu, K., Berry, D., Bandarenko, N., Kerns, B. J., and Iglehart, J. D.
(1994) Overexpression of p53 and Her 2/neu proteins as prognostic markers in early stage breast cancer.
Ann. Surg.
219, 332
341[Medline]
- Rosen, P. P., Lesser, M. L., Arroyo, C. D., Cranor, M., Borgen, P., and Norton, L., et al.
(1995) Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma. A study of epidemiologic risk factors, histologic features and prognosis.
Cancer
75, 1320
1326[Medline]
- Quenel, N., Wafflart, J., Bonichon, F., de Mascarel, I., Trojani, M., Durand, M., Avril, A., and Coindre, J. M.
(1995) The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases.
Breast Cancer Res. Treat.
35, 283
291[Medline]
- Sundblad, A. S., Pellicer, E. M., and Ricci, L.
(1996) Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors.
Hum. Pathol.
27, 297
300[Medline]
- OMalley, F. P., Saad, Z., Kerkvliet, N., Doig, G., Stitt, L., Ainsworth, P., Hundal, H., Chambers, A. F., Turnbull, D. I., and Bramwell, V.
(1996) The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer.
Hum. Pathol.
27, 955
963[Medline]
- Hieken, T. J., Mehta, R. R., and Shilkaitis, A.
(1996) Her-2/neu and p53 expression in breast cancer: Valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry.
Proc. Annu. Meet. Am. Soc. Clin. Oncol.
15, A113
- Xing, W.-R., Gilchrist, K. W., Harris, C. P., Samson, W., and Meisner, L. F.
(1996) FISH detection of HER-2/neu oncogene amplification in early onset breast cancer.
Breast Cancer Res. Treat.
39, 203
212[Medline]
- Dittadi, R., Brazzale, A., Pappagallo, G., Salbe, C., Nascimben, O., Rosabian, A., and Gion, M.
(1997) ErbB2 assay in breast cancer: Possibly improved clinical information using a quantitative method.
Anticancer Res.
17, 1245
1247[Medline]
- Fernandez Acenero, M. J., Farina Gonzalez, J., and Arangoncillo Ballesteros, P.
(1997) Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: Relation with epidemiologic factors, histologic features and prognosis.
Gen. Diagn. Pathol.
142, 289
296[Medline]
- Eissa, S., Khalifa, A., el-Gharib, A., Salah, N., and Mohamed, M. K.
(1997) Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Anticancer Res.
17, 3091
3097[Medline]
- Charpin, C., Garcia, S., Bouvier, C., Martini, F., Lavaut, M. N., Allasia, C., Bonnier, P., and Andrac, L.
(1997) c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients overall and disease-free survival.
Br. J. Cancer
75, 1667
1673[Medline]
- Press, M. J., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R., and Flom, K. J.
(1997) Her-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node negative breast carcinomas.
J. Clin. Oncol.
15, 2894
2904[Abstract]
- Ross, J. S., Muraca, P. J., Jaffe, D., Morgan, T., and Fletcher, J. A.
(1998) Multivariate analysis of prognostic factors in lymph node negative breast cancer.
Mod. Pathol.
11, 26A
- Depowski, P. L., Brien, T. P., Sheehan, C. E., Stylos, S., Johnson, R. L., and Ross, J. S.
(1999) Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
Am. J. Clin. Pathol. TM
112, 459
469[Medline]
- Querzoli, P., Albonico, G., Ferretti, S., Rinaldi, R., Beccati, D., Corcione, S., Indelli, M., and Nenci, I.
(1998) Modulation of biomarkers in minimal breast carcinoma.
Cancer
83, 89
97[CrossRef][Medline]
- Andrulis, I. L., Bull, S. B., Blasckstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., Wilkinson, R., Qizilbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitharm, D., Geddie, W., and McCready, D.
(1998) Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.
J. Clin. Oncol.
16, 1340
1349[Abstract]
- Sjogren, S., Inganas, M., Lindgren, A., Holmberg, L., and Bergh, J.
(1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers.
J. Clin. Oncol.
16, 462
469[Abstract]
- Harbeck, N., Ross, J. S., Yurdseven, S., Dettmar, P., Polcher, M., Kuhn, W., Ulm, K., Graeff, H., and Schmitt, M.
(1999) HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
Int. J. Oncol.
14, 663
671[Medline]
- Scorilas, A., Yotis, J., Pateras, C., Trangas, T., and Talieri, M.
(1999) Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis.
Clin. Cancer Res.
5, 815
821[Abstract/Free Full Text]
- Rudolph, P., Olsson, H., Bonatz, G., Ratjen, V., Bolte, H., Baldetorp, B., Ferno, M., Parwaresch, R., and Alm, P.
(1999) Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications.
J. Pathol.
187, 207
216[CrossRef][Medline]
- Reed, W., Hannisdal, E., Boehler, P. J., Gundersen, S., Host, H., and Marthin, J.
(2000) The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: A multivariate analysis of prognostic factors in 613 patients with a follow-up of 1430 years.
Cancer
88, 804
813[CrossRef][Medline]
- Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., and Slamon, D. J.
(2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry.
J. Clin. Oncol.
18, 3651
3664[Abstract/Free Full Text]
- Kakar, S., Puangsuvan, N., Stevens, J. M., Serenas, R., Mangan, G., Sahai, S., and Mihalov, M. L.
(2000) HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival.
Mol. Diagn.
5, 199
207[CrossRef][Medline]
- Agrup, M., Stal, O., Olsen, K., and Wingren, S.
(2000) C-erbB-2 overexpression and survival in early onset breast cancer.
Breast Cancer Res. Treat.
63, 23
29[CrossRef][Medline]
- Umekita, Y., Ohi, Y., Sagara, Y., and Yoshida, H.
(2000) Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients.
Int. J. Cancer
89, 484
487[CrossRef][Medline]
- Pawlowski, V., Revillion, F., Hebbar, M., Hornez, L., and Peyrat, J. P.
(2000) Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.
Clin. Cancer Res.
6, 4217
4225[Abstract/Free Full Text]
- Volpi, A., De Paola, F., Nanni, O., Granato, A. M., Bajorko, P., Becciolini, A., Scarpi, E., Riccobon, A., Balzi, M., and Amadori, D.
(2000) Prognostic significance of biologic markers in node-negative breast cancer patients: A prospective study.
Breast Cancer Res. Treat.
63, 181
192[CrossRef][Medline]
- Carr, J. A., Havstad, S., Zarbo, R. J., Divine, G., Mackowiak, P., and Velanovich, V.
(2000) The association of HER-2/neu amplification with breast cancer recurrence.
Arch. Surg.
135, 1469
1474[Abstract/Free Full Text]
- Ferrero-Pous, M., Hacene, K., Bouchet, C., Le Doussal, V., Tubiana-Hulin, M., and Spyratos, F.
(2000) Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Clin. Cancer Res.
6, 4745
4754[Abstract/Free Full Text]
- Platt-Higgins, A. M., Renshaw, C. A., West, C. R., Winstanley, J. H., De Silva Rudland, S., Barraclough, R., and Rudland, P. S.
(2000) Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer.
Int. J. Cancer
89, 198
208[CrossRef][Medline]
- Eppenberger-Castori, S., Kueng, W., Benz, C., Caduff, R., Varga, Z., Bannwart, F., Fink, D., Dieterich, H., Hohl, M., Muller, H., Paris, K., Schoumacher, F., and Eppenberger, U.
(2001) Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay.
J. Clin. Oncol.
19, 645
656[Abstract/Free Full Text]
- Jukkola, A., Bloigu, R., Soini, Y., Savolainen, E. R., Holli, K., and Blanco, G.
(2001) c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease.
Eur. J. Cancer
37, 347
354[CrossRef][Medline]
- Gaci, Z., Bouin-Pineau, M. H., Gaci, M., Daban, A., Ingrand, P., and Metaye, T.
(2001) Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Int. J. Oncol.
18, 793
800[Medline]
- Rudolph, P., Alm, P., Olsson, H., Heidebrecht, H. J., Ferno, M., Baldetorp, B., and Parwaresch, R.
(2001) Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
Hum. Pathol.
32, 311
319[CrossRef][Medline]
- Beenken, S. W., Grizzle, W. E., Crowe, D. R., Conner, M. G., Weiss, H. L., Sellers, M. T., Krontiras, H., Urist, M. M., and Bland, K. I.
(2001) Molecular biomarkers for breast cancer prognosis: Coexpression of c-erbB-2 and p53.
Ann. Surg.
233, 630
638[CrossRef][Medline]
- Pinto, A. E., Andre, S., Pereira, T., Nobrega, S., and Soares, J.
(2001) C-erbB-2 oncoprotein overexpression identifies a subgroup of estrogen receptor positive (ER+) breast cancer patients with poor prognosis.
Ann. Oncol.
12, 525
533[Abstract]
- Riou, G., Mathieu, M. C., Barrois, M., Le Bihan, M. L., Ahomadegbe, J. C., Benard, J., and Le, M. G.
(2001) c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients.
Int. J. Cancer
95, 266
270[CrossRef][Medline]
- Horita, K., Yamaguchi, A., Hirose, K., Ishida, M., Noriki, S., Imamura, Y., and Fukuda, M.
(2001) Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Eur. J. Histochem.
45, 73
84[Medline]
- Suo, Z., Risberg, B., Kalsson, M. G., Willman, K., Tierens, A., Skovlund, E., and Nesland, J. M.
(2002) EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
J. Pathol.
196, 17
25[CrossRef][Medline]
- Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., Joensuu, H., and Isola, J.
(2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Cancer Res.
62, 632
635[Abstract/Free Full Text]
- Tsutsui, S., Ohno, S., Murakami, S., Hachitanda, Y., and Oda, S.
(2002) Prognostic value of c-erbB2 expression in breast cancer.
J. Surg. Oncol.
79, 216
223[CrossRef][Medline]
- Spizzo, G., Obrist, P., Ensinger, C., Theurl, I., Dunser, M., Ramoni, A., Gunsilius, E., Eibl, G., Mikuz, G., and Gastl, G.
(2002) Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Int. J. Cancer
98, 883
888[CrossRef][Medline]
- Kato, T., Kameoka, S., Kimura, T., Nishikawa, T., and Kobayashi, M.
(2002) C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
Anticancer Res.
22, 1097
1103[Medline]
- el-Ahmady, O., el-Salahy, E., Mahmoud, M., Wahab, M. A., Eissa, S., and Khalifa, A.
(2002) Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: A short-term follow-up.
Anticancer Res.
22, 2493
2499[Medline]
- Schnitt, S. J., and Jacobs, T. W.
(2001) Current status of HER2 testing: Caught between a rock and a hard place.
Am. J. Clin. Pathol.
116, 806
810[Medline]
- Press, M. F., Hung, G., Godolphin, W., and Slamon, D. J.
(1994) Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression.
Cancer Res.
54, 2771
2777[Abstract]
- Paik, S., Bryant, J., Tan-Chiu, E., Romond, E., Hiller, W., Park, K., Brown, A., Yothers, G., Anderson, S., Smith, R., Wickerham, D. L., and Wolmark, N.
(2002) Real-world performance of HER2 testingNational Surgical Adjuvant Breast and Bowel Project experience.
J. Natl. Cancer Inst.
94, 852
854[Abstract/Free Full Text]
- Paik, S., Tan-chui, E., Bryant, J., Hiller, W., Park, K., and Wolmark, N.
(2002) Successful quality assurance program for HER-2 testing in the NSAPB trial for Herceptin.
Breast Cancer Res. Treat.
76, (Suppl. 1)S31[CrossRef]
- Rhodes, A., Jasani, B., Anderson, E., Dodson, A. R., and Balaton, A. J.
(2002) Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: A comparative study involving results from laboratories in 21 countries.
Am. J. Clin. Pathol.
118, 408
417[Medline]
- Arber, D. A.
(2002) Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers.
Appl. Immunohistochem. Mol. Morphol.
10, 183
186[Medline]
- Wang, S., Saboorian, M. H., Frenkel, E. P., Haley, B. B., Siddiqui, M. T., Gokaslan, S., Wians, F. H., Jr., Hynan, L., and Ashfaq, R.
(2001) Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.
Am. J. Clin. Pathol.
116, 495
503[CrossRef][Medline]
- Bloom, K. J., Torre-Bueno, J., Press, M., Gown, A., Bauer, K., and Harrington, D.
(2000) Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis.
Breast Cancer Res. Treat.
64, 99
- Wang, S., Saboorian, M. H., Frenkel, E., Hynan, L., Gokaslan, S. T., and Ashfaq, R.
(2000) Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridization assays.
J. Clin. Pathol.
53, 374
381[Abstract/Free Full Text]
- Tanner, M., Gancberg, D., Di Leo, A., Larsimont, D., Rouas, G., Piccart, M. J., and Isola, J.
(2000) Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Am. J. Pathol.
157, 1467
1472[Abstract/Free Full Text]
- Zhao, J., Wu, R., Au, A., Marquez, A., Yu, Y., and Shi, Z.
(2002) Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
Mod. Pathol.
15, 657
665[Medline]
- Gupta, D., Middleton, L. P., Whitaker, M. J., and Abrams, J.
(2003) Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.
Am. J. Clin. Pathol.
119, 381
387[Medline]
- Pawlowski, V., Revillion, F., Hornez, L., and Peyrat, J. P.
(2000) A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.
Cancer Detect. Prev.
24, 212
223[Medline]
- Bieche, I., Onody, P., Laurendeau, I., Olivi, M., Vidaud, D., Lidereau, R., and Vidaud, M.
(1999) Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.
Clin. Chem.
45, 1148
1156[Abstract/Free Full Text]
- Tubbs, R. R., Pettay, J. D., Roche, P. C., Stoler, M. H., Jenkins, R. B., and Grogan, T. M.
(2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message.
J. Clin. Oncol.
19, 2714
2721[Abstract/Free Full Text]
- Pusztai, L., Ayers, M., Stec, J., Clark, E., Hess, K., Stivers, D., Damokosh, A., Sneige, N., Buchholz, T. A., Esteva, F. J., Arun, B., Cristofanilli, M., Booser, D., Rosales, M., Valero, V., Adams, C., Hortobagyi, G. N., and Symmans, W. F.
(2003) Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
Clin. Cancer Res.
9, 2406
2415[Abstract/Free Full Text]
- Mackay, A., Jones, C., Dexter, T., Silva, R. L., Bulmer, K., Jones, A., Simpson, P., Harris, R. A., Jat, P. S., Neville, A. M., Reis, L. F., Lakhani, S. R., and OHare, M. J.
(2003) cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells.
Oncogene
22, 2680
2688[CrossRef][Medline]
- Kauraniemi, P., Barlund, M., Monni, O., and Kallioniemi, A.
(2001) New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
Cancer Res.
61, 8235
8240[Abstract/Free Full Text]
- Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P.
(1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens.
Nat. Med.
4, 844
847[Medline]
- Camp, R. L., Charette, L. A., and Rimm, D. L.
(2000) Validation of tissue microarray technology in breast carcinoma.
Lab. Invest.
80, 1943
1949[Medline]
- Andersen, C. L., Hostetter, G., Grigoryan, A., Sauter, G., and Kallioniemi, A.
(2001) Improved procedure for fluorescence in situ hybridization on tissue microarrays.
Cytometry
45, 83
86[CrossRef][Medline]
- Gancberg, D., Di Leo, A., Rouas, G., Jarvinen, T., Verhest, A., Isola, J., Piccart, M. J., and Larsimont, D.
(2002) Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma.
J. Clin. Pathol.
55, 315
317[Abstract/Free Full Text]
- OGrady, A., Flahavan, C. M., Kay, E. W., Barrett, H. L., and Leader, M. B.
(2003) HER-2 analysis in tissue microarrays of archival human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization.
Appl. Immunohistochem. Mol. Morphol.
11, 177
182[Medline]
- Zhang, D., Salto-Tellez, M., Do, E., Putti, T. C., and Koay, E. S.
(2003) Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays.
Hum. Pathol.
34, 362
368[CrossRef][Medline]
- Camp, R. L., Dolled-Filhart, M., King, B. L., and Rimm, D. L.
(2003) Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome.
Cancer Res.
63, 1445
1448[Abstract/Free Full Text]
- Muller, V., Thomssen, C., Karakas, C., Eustermann, I., Ramirez Porras, J., Coith, C., Berger, J., Loning, T., Janicke, F., and Pantel, K.
(2003) Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.
Int. J. Biol. Markers
18, 13
20[Medline]
- Huston, J. S., and George, A. J.
(2001) Engineered antibodies take center stage.
Hum. Antibodies
10, 127
142[Medline]
- Hortobagyi, G. N.
(2001) Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Semin. Oncol.
28, 43
47
- McKeage, K., and Perry, C. M.
(2002) Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2.
Drugs
62, 209
243[CrossRef][Medline]
- Shawver, L. K., Slamon, D., and Ullrich, A.
(2002) Smart drugs: Tyrosine kinase inhibitors in cancer therapy.
Cancer Cell
1, 117
123[CrossRef][Medline]
- Ligibel, J. A., and Winer, E. P.
(2002) Trastuzumab/chemotherapy combinations in metastatic breast cancer.
Semin. Oncol.
29, 38
43
- Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L.
(2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
N. Engl. J. Med.
344, 783
792[Abstract/Free Full Text]
- Schneider, J. W., Chang, A. Y., and Garratt, A.
(2002) Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study.
Semin. Oncol.
29, (Suppl. 11)22
28
- Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., Chien, K. R., Birchmeier, C., and Garratt, A. N.
(2002) Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.
Proc. Natl. Acad. Sci. U. S. A.
99, 8880
8885[Abstract/Free Full Text]
- Nahta, R., and Esteva, F. J.
(2003) HER-2-targeted therapy: Lessons learned and future directions.
Clin. Cancer Res.
9, 5078
5084[Abstract/Free Full Text]
- Nabholtz, J. M., and Crown, J.
(1998) Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Semin Oncol.
25, (Suppl. 13)4
9
- Slamon, D. J., Patel, R., Northfelt, R., Pegram, M., Rubin, J., Sebastian, G., Tannenbaum, S., Sanchez, J., Quan, E., Toppmeyer, D., Overmoyer, B., and Nabholtz, J. M.
(2001) Phase II pilot study of Herceptin combined with taxotere and carboplatin in metastatic breast cancer patients overexpressing the HER-2/neu proto-oncogene: A pilot study of the UCLA network.
Proc. Am. Soc. Clin. Oncol.
20, 193
- HercepTest package insert. Dako Corporation, Glostrup, Denmark.
- Roche, P. C., and Ingle, J. N.
(1999) Increased HER2 with U.S. Food and Drug Administration-approved antibody.
J. Clin. Oncol.
17, 434[Free Full Text]
- Mass, R. D., Press, M. F., Anderson, S., Murphy, M., and Slamon, D.
(2001) Improved survival benefit from Herceptin (Trastuzumab) in patients selected by fluorescence in situ hybridization (FISH).
Proc. ASCO85
- Ogura, H., Akiyama, F., Kasumi, F., Kazui, T., and Sakamoto, G.
(2003) Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry.
Breast Cancer
10, 234
240[Medline]
- Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., and Press, M.
(2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
J. Clin. Oncol.
20, 719
726[Abstract/Free Full Text]
- Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., Gilewski, T., Theodoulou, M., Moynahan, M. E., Moasser, M., Sklarin, N., Dickler, M., DAndrea, G., Cristofanilli, M., Rivera, E., Hortobagyi, G. N., Norton, L., and Hudis, C. A.
(2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
J. Clin. Oncol.
19, 2587
2595[Abstract/Free Full Text]
- Fornier, M., Risio, M., Van Poznak, C., and Seidman, A.
(2003) HER-2 testing and correlation with efficacy in Trastuzumab therapy.
Oncology
16, 1340
1358
- Hammock, L., Lewis, M., Phillips, C., and Cohen, C.
(2003) Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.
Hum. Pathol.
34, 1043
7[CrossRef][Medline]
- Nichols, D. W., Wolff, D. J., Self, S., Metcalf, J. S., Jacobs, D., Kneuper-Hall, R., and Cate, J. C., 4th.
(2002) A testing algorithm for determination of HER2 status in patients with breast cancer.
Ann. Clin. Lab. Sci.
32, 3
11[Abstract/Free Full Text]
- Yaziji, H., and Gown, A. M.
(2002) Testing for HER-2/neu in breast cancer: Is fluorescence in situ hybridization superior in predicting outcome?
Adv. Anat. Pathol.
9, 338
344[Medline]
- Press, M. F., Slamon, D. J., and Flom, K. J.
(2002) Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.
J. Clin. Oncol.
20, 3095
3105[Abstract/Free Full Text]
- Dowsett, M.
(2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
Endocr. Relat. Cancer
8, 191
195[Abstract/Free Full Text]
- Muss, H. B.
(2001) Role of adjuvant endocrine therapy in early-stage breast cancer.
Semin. Oncol.
28, 313
321[CrossRef][Medline]
- Schmid, P., Wischnewsky, M. B., Sezer, O., Bohm, R., and Possinger, K.
(2002) Prediction of response to hormonal treatment in metastatic breast cancer.
Oncology
63, 309
316[CrossRef][Medline]
- Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H. M., Bauerfeind, I., Felber, M., Wang, H. J., Beryt, M., Seshadri, R., Hepp, H., and Slamon, D. J.
(2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
J. Natl. Cancer Inst.
95, 142
153[Abstract/Free Full Text]
- Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., DAntonio, A., Bianco, A. R., and De Placido, S.
(1996) CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases.
J. Clin. Oncol.
14, 2702
2708[Abstract]
- Elledge, R. M., Green, S., Ciocca, D., Pugh, R., Allred, D. C., Clark, G. M., Hill, J., Ravdin, P., OSullivan, J., Martino, S., and Osborne, C. K.
(1998) HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study.
Clin. Cancer Res.
4, 7
12[Abstract]
- De Placido, S., De Laurentiis, M., Carlomagno, C., Gallo, C., Perrone, F., Pepe, S., Ruggiero, A., Marinelli, A., Pagliarulo, C., Panico, L., Pettinato, G., Petrella, G., and Bianco, A. R.
(2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
Clin. Cancer Res.
9, 1039
1046[Abstract/Free Full Text]
- Ravdin, P. M., Green, S., Albain, V., Boucher, V., Ingle, J., Pritchard, K., Shepard, L., Davidson, N., Hayes, D. F., Clark, G. M., Martino, S., Osborne, C. K., and Allred, D. C.
(1998) Initial report of the SWOG biologicalcorrelative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone.
Proc. ASCO
17, 97a
- Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., and Borgs, M.
(2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial.
J. Clin. Oncol.
19, 3808
3816[Abstract/Free Full Text]
- Berns, E. M., Foekens, J. A., van Staveren, I. L., van Putten, W. L., de Koning, H. Y., Portengen, H., and Klijn, J. G.
(1995) Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment.
Gene
159, 11
18[CrossRef][Medline]
- Sparano, J. A.
(2000) Taxanes for breast cancer: An evidence-based review of randomized phase II and phase III trials.
Clin. Breast Cancer
1, 32
40[Medline]
- Yu, D.
(2001) Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers.
Semin. Oncol.
28, (Suppl. 16)12
17
- Baselga, J., Seidman, A. D., Rosen, P. P., and Norton, L.
(1997) HER-2 overexpression and paclitazel sensitivity in breast cancer: therapeutic implications.
Oncology
11, 43
48
- Kim, R., Tanabe, K., and Uchida, Y.
(2002) The role of HER-2 oncoprotein in drug-sensitivity in breast cancer.
Oncol. Rep.
9, 3
9[Medline]
- Hamilton, A., Larsimont, D., Paridaens, R., Drijkoningen, M., van de Vijver, M., Bruning, P., Hanby, A., Houston, S., Treilleux, I., Guastalla, J. P., Van Vreckem, A., Sylvester, R., and Piccart, M.
(2000) A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: A companion study to EORTC 10923.
Clin. Breast Cancer.
1, 233
240[Medline]
- Di Leo, A., Larsimont, D., Gancberg, D., Jarvinen, T., Beauduin, M., Vindevoghel, A., Michel, J., Focan, C. H., Ries, F., Gobert, P. H., Closon-Dejardin, M. T., Dolci, S., Rouas, G., Paesmans, M., Lobelle, J. P., Isola, J., and Piccart, M. J.
(2001) HER-2 and topo-isomerase II alpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
Ann. Oncol.
12, 1081
1089[Abstract]
- Petit, T., Borel, C., Ghnassia, J. P., Rodier, J. F., Escande, A., Mors, R., and Haegele, P.
(2001) Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
Clin. Cancer Res.
7, 1577
1581[Abstract/Free Full Text]
- Harris, L. N., Yang, L., Liotcheva, V., Pauli, S., Iglehart, J. D., Colvin, O. M., Hsieh, T. S.
(2001) Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy.
Clin. Cancer Res.
7, 1497
1504[Abstract/Free Full Text]
- Zhang, F., Yang, Y., Smith, T., Kau, S. W., McConathy, J. M., Esteva, F. J., Kuerer, H. M., Symmans, W. F., Buzdar, A. U., Hortobagyi, G. N., and Pusztai, L.
(2003) Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Cancer
97, 1758
1765[CrossRef][Medline]
- Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J.
(1997) The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Oncogene
15, 537
547[CrossRef][Medline]
- Jarvinen, T. A., Holli, K., Kuukasjarvi, T., and Isola, J. J.
(1998) Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemo-therapy in advanced breast cancer.
Br. J. Cancer
77, 2267
2273[Medline]
- Jarvinen, T. A., and Liu, E. T.
(2003) Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancerMore common than anticipated.
Cytopathology
14, 309
313[CrossRef][Medline]
- Depowski, P. L., Rosenthal, S. I., Brien, T. P., Stylos, S., Johnson, R. L., and Ross, J. S.
(2000) Topoisomerase II alpha expression in breast cancer: correlation with outcome variables.
Mod. Pathol.
13, 542
547[Medline]
- Jarvinen, T. A., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., and Isola, J.
(2000) Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
Am. J. Pathol.
156, 839
847[Abstract/Free Full Text]
- Tanner, M., Jarvinen, P., and Isola, J.
(2001) Amplification of HER-2/neu and topoisomerase II alpha in primary and metastatic breast cancer.
Cancer Res.
61, 5345
5348[Abstract/Free Full Text]
- Park, K., Kim, J., Lim, S., and Han, S.
(2003) Topoisomerase II-alpha (topoll) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.
Eur. J. Cancer
39, 631
634[CrossRef][Medline]
- Di Leo, A., Gancberg, D., Larsimont, D., Tanner, M., Jarvinen, T., Rouas, G., Dolci, S., Leroy, J. Y., Paesmans, M., Isola, J., and Piccart, M. J.
(2002) HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Clin. Cancer Res.
8, 1107
1116[Abstract/Free Full Text]
- Coon, J. S., Marcus, E., Gupta-Burt, S., Seelig, S., Jacobson, K., Chen, S., Renta, V., Fronda, G., and Preisler, H. D.
(2002) Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer.
Clin. Cancer Res.
8, 1061
1067[Abstract/Free Full Text]
- Haffty, B. G., Brown, F., Carter, D., and Flynn, S.
(1996) Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study.
Int. J. Rad. Oncol. Biol. Phys.
35, 751
757[CrossRef][Medline]
- Yamauchi, H., ONeill, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S., and Hayes, D. F.
(1997) Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
J. Clin. Oncol.
15, 2518
2525[Abstract]